PASTEUR Act

Bill: 118-hr-2940
Sponsor: Rep. Ferguson, A. Drew, IV [R-GA-3]
Introduced: 2023-04-27 in the House
Policy area: Health
Subjects: Administrative law and regulatory procedures
Advanced technology and technological innovations
Advisory bodies
Appropriations
Department of Health and Human Services
Drug therapy
Executive agency funding and structure
Government information and archives
Government studies and investigations
Health information and medical records
Infectious and parasitic diseases
Medical research
Prescription drugs
Public contracts and procurement
Research and development

Summary:
action_date: 2023-04-27
text: 

Pioneering Antimicrobial Subscriptions To End Upsurging Resistance Act of 2023 or the PASTEUR Act

 of 

2023

 
This bill authorizes the Department of Health and Human Services (HHS) to enter into subscription contracts for critical-need antimicrobial drugs, provides $6 billion in appropriations for activities under the bill, and contains other related provisions. 
 
A manufacturer of a Food and Drug Administration-approved antimicrobial drug may apply to HHS to have the drug designated as a critical-need antimicrobial, and HHS may enter into a subscription contract for such a critical-need antimicrobial. The bill imposes certain requirements related to such contracts, including a mechanism to lower payments under the contract in certain instances to limit the manufacturer's revenue from the drug. 
 
Furthermore, HHS and the Centers for Disease Control and Prevention (CDC) shall award grants to support efforts to encourage the appropriate use of antimicrobial drugs and efforts to combat antimicrobial resistance. The CDC shall also track and assess data relating to antibacterial resistance and human antibiotic use and make such data publicly available.
 
HHS shall also establish a Committee on Critical Need Antimicrobials. The committee shall develop a list of prioritized infections for which new antimicrobial drug development is needed, among other duties.
 
Within six years of the bill's enactment, the Government Accountability Office shall report to Congress a study on the bill's effectiveness in developing priority antimicrobial drugs.


Legislative actions:
action_date: 2024-12-17
text: Referred to the Subcommittee on Health.
action_date: 2023-04-28
text: Referred to the Subcommittee on Health.
action_date: 2023-04-27
text: Referred to the Committee on Energy and Commerce, and in addition to the Committees on Oversight and Accountability, Ways and Means, and the Budget, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
action_date: 2023-04-27
text: Referred to the Committee on Energy and Commerce, and in addition to the Committees on Oversight and Accountability, Ways and Means, and the Budget, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
action_date: 2023-04-27
text: Referred to the Committee on Energy and Commerce, and in addition to the Committees on Oversight and Accountability, Ways and Means, and the Budget, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
action_date: 2023-04-27
text: Referred to the Committee on Energy and Commerce, and in addition to the Committees on Oversight and Accountability, Ways and Means, and the Budget, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
action_date: 2023-04-27
text: Introduced in House
action_date: 2023-04-27
text: Introduced in House